Sermorelin dosage reference: typical range 200–500 mcg, 2×/week to daily (5-on/2-off), cycle 3–6 months on, 4–6 weeks off. Titration chart, reconstitution…
A bioidentical growth hormone-releasing hormone that stimulates the pituitary to produce natural GH. Gold standard for anti-aging clinics; promotes natural GH pulsatility.
Published protocol literature for Sermorelin describes a typical range of 200–500 mcg, dosed 2×/week to daily (5-on/2-off), over a cycle of 3–6 months on, 4–6 weeks off. Reported half-life: 10–20 minutes.
| Parameter | Reported value |
|---|---|
| Typical dose range | 200–500 mcg |
| Frequency | 2×/week to daily (5-on/2-off) |
| Cycle length | 3–6 months on, 4–6 weeks off |
| Half-life | 10–20 minutes |
| Route | Subcutaneous injection (most published protocols) |
| Diluent | Bacteriostatic water |
| Commonly stacked with | Ipamorelin (synergistic GH pulse), CJC-1295 (extended duration), MK-677 (oral support) |
Protocols are usually titrated rather than started at the top of the range. The tiers below reflect how Sermorelin dosing is commonly stepped in the published protocol literature.
| Tier | Dose | Frequency | Notes |
|---|---|---|---|
| Beginner | 200 mcg | 2×/week | Entry level; subtle benefits in 4–6 weeks |
| Intermediate | 300 mcg | 3×/week (M/W/F) | Noticeable strength and recovery |
| Advanced | 300–500 mcg | Daily (5-on/2-off) | Max benefits; monitor IGF-1 levels |
Concentration in mcg/mL equals vial milligrams multiplied by 1000, divided by the millilitres of bacteriostatic water added. Volume per dose in mL equals the target dose in mcg divided by that concentration. On a U-100 insulin syringe, multiply the volume in mL by 100 to read the units.
| Vial | Bacteriostatic water | Resulting concentration |
|---|---|---|
| 2 mg vial | 1 mL bacteriostatic water | 2,000 mcg/mL |
| 5 mg vial | 1 mL bacteriostatic water | 5,000 mcg/mL |
| 10 mg vial | 2 mL bacteriostatic water | 5,000 mcg/mL |
| State | Conditions | Shelf life |
|---|---|---|
| Lyophilized (Powder) | Refrigerate 2–8°C (36–46°F) or freeze | 12–24 months refrigerated; longer frozen |
| Reconstituted | Refrigerate 2–8°C only; no freezing | 21–30 days typically |
| In Transit | Insulated packaging; ice packs | Minimize time; avoid heat exposure |
| MK-677 (Oral) | Room temp okay; cool/dry preferred | Per manufacturer; typically 12+ months |
Dose ranges on this page summarise published research and practitioner protocol literature for Sermorelin. They are a reference, not medical direction. All peptide products referenced are intended solely for research, investigational, or licensed professional use. They are not FDA-approved and are not intended to diagnose, treat, cure, or prevent any disease. Consult a licensed medical practitioner before any personal or clinical use.
Published protocol literature for Sermorelin generally describes 200–500 mcg, administered 2×/week to daily (5-on/2-off). Individual protocols vary and should be set by a licensed practitioner.
2×/week to daily (5-on/2-off). Frequency is driven by half-life — Sermorelin has a reported half-life of 10–20 minutes, so shorter-acting compounds are dosed more often.
Typical cycle length reported is 3–6 months on, 4–6 weeks off. Cycling exists to limit receptor desensitisation and to create assessment windows, not as a fixed rule.
2mg → 1ml bacteriostatic water; 5mg → 1ml bacteriostatic water; 10mg → 2ml bacteriostatic water. Concentration in mcg/mL equals vial milligrams times 1000 divided by millilitres of bacteriostatic water.
Both target the GHRH receptor. CJC-1295 is engineered for greater stability and longer action than the parent Sermorelin molecule.